Thanks for writing this up; more reasons to be optimistic!
I’m less clear on this, but it looks like the next step is that the trial data will be reviewed by the WHO; I’m not sure if there’s room to speed that up or encourage recommendation of the new regimens to the extent it should be encouraged
Looks like the next step is an already-funded Phase III trial due to finish in mid 2025. Don’t think there’s much scope to speed that up, but looking at the number of regimens tested, it looks hopeful that at least one of them will end up being a cost effective intervention.
Ah—where are you seeing that? The endTB page mentions under “What’s next?” the phase III endTB-Q trial, but that’s for pre-XDR TB, with “results [...] expected in late 2024″.
You’re right, I picked up the endTB-Q trial expected to announce findings in 2025, but missed that endTB-Q had a different target (fluoroquinolone-resistant MDR-TB) and wasn’t just a continuation of the previous tests with a different drug cocktail.
Thanks for writing this up; more reasons to be optimistic!
Looks like the next step is an already-funded Phase III trial due to finish in mid 2025. Don’t think there’s much scope to speed that up, but looking at the number of regimens tested, it looks hopeful that at least one of them will end up being a cost effective intervention.
Ah—where are you seeing that? The endTB page mentions under “What’s next?” the phase III endTB-Q trial, but that’s for pre-XDR TB, with “results [...] expected in late 2024″.
You’re right, I picked up the endTB-Q trial expected to announce findings in 2025, but missed that endTB-Q had a different target (fluoroquinolone-resistant MDR-TB) and wasn’t just a continuation of the previous tests with a different drug cocktail.